Cantor Fitzgerald Comments on VERA FY2026 Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Vera Therapeutics in a report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings of ($2.28) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $100.00 price objective on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share.

Several other equities analysts also recently commented on the company. Scotiabank reaffirmed an "outperform" rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. Wedbush lowered their target price on Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Guggenheim restated a "buy" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. HC Wainwright restated a "buy" rating and set a $85.00 price objective (up from $75.00) on shares of Vera Therapeutics in a research note on Monday, June 2nd. Finally, JPMorgan Chase & Co. decreased their price objective on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research note on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $65.00.

Vera Therapeutics Trading Up 1.0%

Shares of NASDAQ VERA traded up $0.22 during trading hours on Wednesday, hitting $22.74. 1,306,850 shares of the company traded hands, compared to its average volume of 949,096. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -8.71 and a beta of 1.13. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The company's 50 day moving average price is $22.52 and its 200 day moving average price is $30.62. Vera Therapeutics has a 12 month low of $18.53 and a 12 month high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same period last year, the company earned ($0.56) earnings per share.

Institutional Investors Weigh In On Vera Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers raised its stake in Vera Therapeutics by 7.9% in the first quarter. Rhumbline Advisers now owns 63,189 shares of the company's stock valued at $1,518,000 after buying an additional 4,600 shares during the last quarter. Jane Street Group LLC raised its stake in Vera Therapeutics by 297.1% in the first quarter. Jane Street Group LLC now owns 41,578 shares of the company's stock valued at $999,000 after buying an additional 62,678 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Vera Therapeutics by 22.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company's stock valued at $2,354,000 after buying an additional 17,907 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Vera Therapeutics in the first quarter valued at about $326,000. Finally, Parkman Healthcare Partners LLC purchased a new stake in Vera Therapeutics in the first quarter valued at about $1,829,000. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.